Trial Profile
Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction: A Double-blind Randomized Controlled Phase IV Trial (VASCEND)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2020
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms VASCEND
- 03 Nov 2020 Status changed from recruiting to completed.
- 25 Oct 2019 Planned End Date changed from 30 Jun 2019 to 31 May 2020.
- 25 Oct 2019 Planned primary completion date changed from 30 Jun 2019 to 31 May 2020.